GlassScriptPhysician profile
Virginia C Araiza
NPI 1164757712
$151,271.58
in general payments reported to CMS, 2019-2025
30 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Pediatric Endocrinology providers received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56K · 2020: $16K · 2021: $8,902 · 2022: $9,594 · 2023: $5,588 · 2024: $40K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $44K · Travel and Lodging: $13K · Food and Beverage: $4,750.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $43,500.00 |
| Travel and Lodging | $12,928.63 |
| Food and Beverage | $4,749.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $145,901.34 | 2019-2025 | Strensiq |
| Abbvie INC. | $1,402.63 | 2019-2025 | Lupron Depot, Synthroid |
| Novo Nordisk INC | $728.92 | 2019-2025 | Sogroya, Norditropin |
| Abbott Laboratories | $510.22 | 2020-2024 | Freestyle Libre |
| Tandem Diabetes Care, INC. | $335.87 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Insulet Corporation | $326.49 | 2019-2024 | Omnipod |
| Dexcom, INC. | $276.23 | 2019-2025 | Dexcom G6 Transmitter |
| Sanofi-Aventis U.S. LLC | $236.24 | 2021-2025 | |
| Xeris Pharmaceuticals, INC. | $233.95 | 2021-2025 | Gvoke Hypopen |
| Ascendis Pharma Endocrinology INC | $162.06 | 2022-2025 | Skytrofa |
| Tris Pharma INC | $124.40 | 2019 | |
| Cequr Corporation | $111.98 | 2022 | |
| Amphastar Pharmaceuticals, INC. | $103.05 | 2024-2025 | |
| Ibsa Pharma INC. | $94.77 | 2019-2024 | Licart, Tirosint |
| Neurocrine Biosciences, INC. | $85.29 | 2024-2025 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $84.66 | 2021-2022 | |
| Companion Medical, INC. | $76.71 | 2019-2020 | |
| Eton Pharmaceuticals, INC. | $72.94 | 2023-2024 | Alkindi |
| Pfizer INC. | $64.35 | 2019-2021 | |
| Amneal Pharmaceuticals LLC | $53.81 | 2021-2023 | Unithroid |
| Azurity Pharmaceuticals, INC. | $49.13 | 2024 | Triptodur |
| Ferring Pharmaceuticals INC. | $47.65 | 2019 | |
| Endo USA, INC. | $43.04 | 2025 | Supprelin |
| Beta Bionics, INC. | $29.38 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
| Lilly USA, LLC | $26.24 | 2019-2022 | |
| Tolmar, INC. | $24.81 | 2024 | |
| Soleno Therapeutics, INC. | $23.71 | 2025 | Vykat Xr |
| Kyowa Kirin, INC. | $14.82 | 2024 | Crysvita |
| Ultragenyx Pharmaceutical INC. | $14.06 | 2021 | |
| Cranial Technologies, INC | $12.83 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Virginia Araiza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.